Bibliography
- RAY AS, OLSON L, FRIDLAND A:Mechanism of the drug interaction between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 3.
- ••Also published in Antimicrob. AgentsChemother. (2004) 48(4):1089–1095, this in vitro study demonstrates tenofovir monophosphate and -diphosphate can significantly inhibit purine nucleoside phosphorylase, the enzyme involved in didanosine and endogenous purine catabolism.
- TURRIZIANI O, BUTERA O,MAFFEO A et al.: Thymidine kinase and deoxycytidine kinase activity in peripheral blood mononuclear cells from HIV seropositive antiretroviral naive individuals. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract?.
- YEH R, GAVER V, PARK J et al.: Lopinavir/ritonavir induces CYP 2C9 and 2C19 activity as measured by warfarin and omeprazole biomarkers in healthy human volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 13.
- HOETELMANS R, LEFEBVRE E, VAN DER SANDT I et al: Pharmacokinetics and effect of food on TMC114, a potent next generation protease inhibitor, boosted with low-dose ritonavir. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 39.
- BOFFITO M, BACK D, DICKINSON L et al.: Saquinavir hard gel (SQV-HG)/ritonavir (RTV) pharmacokinetics (PK): effect of high fat meals, plasma concentration, diurnal variation and intrapatient variability. 5h International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 65.
- ANANWORANICH J, HILL A, SIANGPHOE U et al: Short-term HIV RNA reductions independent of saquinavir Cmin - analysis of 73 Thai patients given saquinavir/ritonavir with two NRTIs. 5h International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 75.
- BERTZ R, CHIU Y-L, FOIT C et al:Estimation of selective pressure by lopinavir/ritonavir (LPV/r) versus nelfinavir (NFV) by examination of terminal-phase pharmacokinetics (PK) at steady-state. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 44.
- •An interesting, but controversial, hypothesis relating plasma protease inhibitor concentrations to the development of resistance.
- HYLAND R, JONES P, MUIRHEAD G: In vitro assessment of the CYP -based drug-drug interaction potential of UK-427,857. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004).
- BONORA S, CASTAGNA A, AGUILAR MARUCCO D et al.: Inter- and intra-individual variability of enfuvirtide plasma trough concentrations in the clinical setting. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 46.
- RAY A, VELA E, OLSON L et al: Lack of interaction between tenofovir and abacavir in human cells. 3' International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 5.
- HAWKINS T, VEIKLEY W, STCLAIRE R et al.: Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 6.
- KRUSE G, STOCKER H, BRESKE A et al.: Trough levels of seven different atazanavir regimens in HIV-infected patients. 3' International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 6.6.
- BOFFITO M, D'AVOLIO A, DI PERRI G et al.: Repeated pharmacokinetics of tenofovir disoproxil fumarate (TDF) in HIV-infected adults receiving saquinavir (SQV) hard gel/ritonavir (RTV) 1000/100 mg BID. 5' International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 31.
- •Tenofovir does not interact with saquinavir/ritonavir 1000/100 mg b.i.d.
- ANANWORANICH J, SIANGPHOE U, MAHANONTHARIT A et al.: Saquinavir Cmfr, before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. 5h International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 27.
- •Tenofovir does not interact with saquinavir/ritonavir 1600/100 mg/day.
- BOYD M, AUTAR R, SIANGPHOE U et al.: Saquinavir 1000 mg BID boosted with ritonavir 200 mg in the presence of efavirenz 600 mg results in adequate saquinavir minimum concentrations: HIV-NAT 012 pharmacokinetic study.gth International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 21.
- ••Trough concentrations of saquinavirdeclined over 12 weeks of treatment, suggesting the full induction effect by efavirenz may not be adequately captured in short-term pharmacokinetic interaction studies.
- CANTA F, MARRONE R,GONZALEZ DE REQUENA D et al: Pharmacokinetics of atazanavir (ATV) alone and coadministered with saquinavir hard-gel capsules (SQVhgc) once daily.gth International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 33.
- •The recommended dose of saquinavir with atazanavir is saquinavir hard-gel/atazanavir 1600/400 mg/day or saquinavir hard-gel/atazanavir/ritonavir 1600/300/100 mg/day.
- BOFFITO M, BACK D, KUROWSKI M et al.: Pharmacokinetics (PK) of saquinavir hard gel (SQV)/ritonavir (RTV) with atazanavir (ATV) or fosamprenavir (FPV) in HIV+ patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 17.
- •The recommended dose of saquinavir with fosarnprenavir is saquinavir hard-gel 1000 mg, fosarnprenavir 700 mg and ritonavir 200 mg (all
- BERTZ R, ASHBRENNER E, FOIT C et al.: Assessment of the steady-state pharmacokinetics of three dosing regimens of saquinavir (400, 600 and 800 mg twice daily) administered as the hard gelatin capsule (HGC) in combination with lopinavir/ritonavir (LPV/r) 400/100 mg BID in HIV-infected adults. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 18.
- STASZEWSKI S, DAUER B, CARLEBACH A et al.: The LOPSAQ study: 12-hour pharmacokinetic analysis of HIV+ patients treated with the salvageregimen lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) Therapy, 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 47.
- GUFFANTI M, VILLANI P, SEMINARI E et al.: Atazanavir (ATV) pharmacokinetics when combined with amprenavir (APV) in highly experienced HIV-positive patients. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 22.
- VAN HEESWIJK R, SABO JP, MACGREGOR TR et al: The effect of tipranavir/ritonavir 500/200 mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volunteers. gh International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 20.
- VAN HEESWIJK R, SABO JP,COOPER C et al: The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP 3A4 in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 35.
- •Atorvastatin should not be co-administered with tipranavir/ritonavir.
- CURRY K, SAMUELS C, LEITH J et al:Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or incombination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI 1182.51.
- •Given the significant reduction in amprenavir, lopinavir and saquinavir concentrations when combined with tipranavir/ritonavir and the poor virological outcome in this study — combining a protease inhibitor with tipranavir/ritonavir is not recommended.
- AZUAJE C, LOPEZ R, RIBERA E et al: Pharmacokinetics and efficacy of once daily regimen with saquinavir, ritonavir, didanosine and lamivudine in patients with tuberculosis and HIV infection (TBQD study). 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004):Abstract 14.
- DROSTE JAH, KEARNEY BP, HORSSEN P et al.: Lack of clinically relevant interaction between tenofovir DF and rifampin in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004) Abstract 23.
- JENKINS T, ABEL S, RUSSELL D et al: The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427,857, in healthy volunteers. 5th International Workshop on ClinicalPharmacology of HIV Therapy Rome, Italy (2004).
- ABEL S, RUSSELL D, RIDGWAY C et al:Effect of CYP 3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. 5h International Workshop on Clinical Pharmacology of HIV Therapy Rome, Italy (2004).Websites
Websites
- http://www.HIVpresentation.com 5th International Workshop on Clinical Pharmacology of HIV Therapy, All conference materials, such as presentations, posters, abstracts and meeting report are on-line available.
- http://www.virology-education.com Virology Education. This site focuses on the initiation and organisation of high profile medical courses and workshops.